Research & Development

Roivant launches biopharmaceutical firm to develop therapeutics for respiratory diseases

Roivant Sciences has launched Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases.

Pfizer to evaluate Atomwise’s platform to identify drug candidates for three target proteins

Atomwise, a provider of Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer.

Allergan to buy clinical-stage biotechnology firm Bonti for $195m

Irish drug maker Allergan has agreed to acquire US-based clinical-stage biotech company Bonti in a deal worth more than $195m.

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m

Boehringer Ingelheim has purchased all shares of Austrian biopharmaceutical firm, ViraTherapeutics, in a deal valued at around €210m.

Immunotherapy firm OncoResponse secures $40m series B financing

OncoResponse, an immunotherapy company developing a portfolio of novel antibodies for cancer, has announced the completion of a $40m series B equity financing.

Summit discovers new mechanism antibiotics to combat ESKAPE pathogen targets

Summit Therapeutics, a UK-based clinical-stage drug discovery and development company, claims to have discovered multiple new mechanism antibiotics against novel ESKAPE pathogen targets.

Fulcrum raises $80m funding to advance rare disease-focused pipeline

Fulcrum Therapeutics, a company engaged in discovery and development of small molecule therapies for the treatment of serious genetic diseases, has raised $80m in a Series B funding round.

Boehringer, Tsinghua University to develop immunological therapies for infectious diseases

German pharma company Boehringer Ingelheim has announced a collaboration with Tsinghua University in Beijing to research and develop immunological therapies for infectious diseases.

Evotec, CHDI Foundation expand collaboration for Huntington’s disease

CHDI Foundation has extended its collaboration with Evotec through to 2023 to fight against Huntington's disease, a familial disease caused by a mutation in the huntingtin gene.